Where Europe’s ‘BeNeLuxA’ Joint Pricing Pilot May Have Gone Wrong
A more innovative approach to pricing and reimbursement arrangements is needed in the pilot BeNeLuxA joint pricing negotiations, says Eurordis head Yann Le Cam. The Netherlands and Belgium are expected to re-start the negotiations soon after a “time-out” period.
You may also be interested in...
BeNeLuxA, the cross-country medicines access initiative, says it is now the “gold standard” for voluntary collaboration in Europe after a ground-breaking deal was reached with Novartis.
The Valletta Group says that cancer drugs, treatments for autoimmune diseases, orphan medicines and biosimilars are among the products it is targeting in its joint procurement efforts.
In a BeNeLuxA first, Belgium and the Netherlands have reached an agreement with Biogen to reimburse rare disease treatment Spinraza after joint health technology assessment and pricing negotiations.